Skip to main content
Przejdź do strony domowej Komisji Europejskiej (odnośnik otworzy się w nowym oknie)
polski pl
CORDIS - Wyniki badań wspieranych przez UE
CORDIS

Advancing syphilis control: elucidating novel dynamics for vaccine target discovery

Cel

Treponema pallidum (TP), the causative agent of syphilis, along with other pathogenic spirochetes, forms a distinct evolutionary clade with unique features including periplasmic endo-flagella, minimal genomes, and outer membranes lacking lipopolysaccharides. These features enable TP to navigate viscous environments, breach biological barriers, and evade host immune responses, leading to severe diseases affecting over 7 million people globally each year. While vaccine development is vital to controlling syphilis, there is currently little consensus on effective vaccine targets. Clinically relevant strains and infection models are needed to deepen our understanding of TP's biology, without which vaccine progress will be challenging. This is urgent since syphilis infects 1 million pregnant women and causes 200,000 stillbirths annually, making it the second leading cause of stillbirths after malaria.
Research on TP is hindered by its dependence on host cells for growth, complicating in vitro cultivation and leaving critical questions unanswered. ASCEND will address these gaps by unraveling TP's distinctive biology and host interactions, using multi-omics approaches and cutting-edge techniques like spatial transcriptomics. Specifically, I will identify TP's host dependencies and optimize axenic (cell-free) culture conditions to isolate and grow TP directly from clinical samples, enabling the use of clinically relevant strains for experimentation. Furthermore, I will identify TP adhesins and characterize their roles in attachment and cell cycle, positioning them as prime vaccine candidates to block infection at its earliest stage. Finally, skin organoids will be employed, for the first time, to investigate host-pathogen interactions in 3D under conditions that better mimic human disease than monolayer culture. Ultimately, ASCEND will seek to identify effective vaccine candidates and improve understanding of TP biology to combat syphilis

Dziedzina nauki (EuroSciVoc)

Słowa kluczowe

Program(-y)

Temat(-y)

System finansowania

HORIZON-ERC - HORIZON ERC Grants

Wyświetl wszystkie projekty finansowane w ramach tego programu finansowania

Zaproszenie do składania wniosków

(odnośnik otworzy się w nowym oknie) ERC-2025-STG

Wyświetl wszystkie projekty finansowane w ramach tego zaproszenia

Instytucja przyjmująca

LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER
Wkład UE netto
€ 1 430 237,00
Adres
KEPPEL STREET
WC1E 7HT London
Zjednoczone Królestwo
Region
London Inner London — West Camden and City of London
Rodzaj działalności
Higher or Secondary Education Establishments
Linki
Koszt całkowity
€ 1 430 237,00

Beneficjenci (1)